

OREGON HEALTH AUTHORITY
IMMUNIZATION PROTOCOL FOR PHARMACISTS
PNEUMOCOCCAL CONJUGATE VACCINE: PCV13 (Pneumovax[®] 13)¹
AND
PNEUMOCOCCAL POLYSACCHARIDE VACCINE: PPSV23 (Pneumovax[®] 23)²

01-2016

- Vaccination age changed to clients ≥ 7 years of age

On 09-03-2015, the Advisory Committee on Immunization Practices (ACIP) published the following recommendation. See page 8 for algorithms: ³

- For healthy ^{*} adults ≥ 65 years of age:
 - Begin the adult pneumococcal series with PCV13 whenever possible.
 - Interval spacing between any PCV13 and PPSV23 dose is ≥ 1 year, regardless of which dose is given first.
 - If either PCV13 or PPSV23 is inadvertently given less than 12 months apart, do not repeat either dose.
 - PCV13 and PPSV23 cannot be given at the same visit.
- Recommended interval for high-risk[◇] persons ≥ 65 years:
 - ≥ 8 weeks between PCV13 and PPSV23.
 - ≥ 1 year between PPSV23 and PCV13.
- Recommended intervals for high-risk[◇] persons < 65 years of age have not changed:
 - 19–64: ≥ 8 weeks from PCV13 to PPSV23
 - 19–64: ≥ 1 year from PPSV23 to PCV13
 - 2–18: 8-week interval spacing between PPSV23 and PCV13, regardless of which was given first
 - < 12 months: 4 weeks between doses of PCV13. See page 5.
- Addition of section III C on page 6 to clarify the order for healthy children 24–59 months.
- Replacement of the check-mark table with a new color-coded chart; now page 11.

^{*} No underlying chronic conditions. ³

[◇] See Section III. F., page 9, for list of high-risk conditions. ³

OREGON IMMUNIZATION PHARMACY PROTOCOL: on next page

I. OREGON IMMUNIZATION PHARMACY PROTOCOL:

1. Check the ALERT Immunization Information System (IIS) to determine whether the patient needs this vaccine and any other vaccines.
2. Screen clients ≥ 7 years of age for contraindications.
3. Provide a current Vaccine Information Statement (VIS) and answer any questions.
4. Record all required data elements in patient's permanent health record.
5. Pneumococcal vaccines:
 - a) Give 0.5mL PCV13 vaccine (Pneumovax[®] 13)¹ intramuscularly (IM) to eligible clients. See Section III. A–G, pages 3–7. **OR**
 - b) Give 0.5 mL PPSV23 vaccine (Pneumovax[®] 23)² IM, or subcutaneously (SC) to eligible clients. See Section V. A, page 11.
6. Either Pneumovax[®] 13 or Pneumovax[®] 23, (but not both) may be given simultaneously with influenza and most ACIP-recommended child and adult vaccinations.*
7. Ask client to remain seated on the premises for 15 minutes after vaccination to decrease the risk of injury should they faint.

Pharmacist Signature

Date

II. A. U.S. LICENSED PNEUMOCOCCAL VACCINES[§]

Product Name	Vaccine Components	Acceptable Age Range	Thimerosal	FDA Approved?
Prevnar 13® (Wyeth/Pfizer) PCV13	Polysaccharide conjugate of 13 serotypes of <i>Streptococcus pneumoniae</i>	6 weeks–5 years	None	Yes
		6–18 years with selected high-risk conditions ^{§5}	None	Yes
		19–49 years with selected high-risk conditions ^{*∠§6}	None	No [*]
		50–64 years of age with selected high-risk conditions ^{∠§}	None	Yes
		≥65 years of age	None	Yes
Pneumovax®23 (Merck & Co.) PPSV23	Capsular polysaccharide of 23 serotypes of <i>Streptococcus pneumoniae</i>	≥2 years of age with selected high-risk conditions ^{‡2} OR ≥65 years of age	None	Yes

*ACIP’s off-label provisional recommendations advise that children and adults with selected high-risk conditions should receive this vaccine (Section IV pg.10).^{5,7}

∠ACIP does not recommend PCV13 or PPSV23 for healthy individuals 19–64 years of age.

[§]Do not repeat either PCV13 or PPSV23 if both doses are inadvertently given simultaneously or if either PCV13 or PPSV23 is given earlier than the recommended interval.^{3, 6}

[‡]See Section IV page 11 for high-risk conditions.

III. A. SCHEDULE FOR PREVNAR 13® (PCV13)

Primary PCV13 series and booster for infants 6 weeks–15 months: Table 8

Dose	Minimum Age ²	Minimum Spacing ^{*◇}	Recommended Age
1	6 weeks		2 months
2	10 weeks	4 weeks after dose #1	4 months
3	14 weeks	4 weeks after dose #2	6 months
4 (Booster)	12 months	8 weeks after dose #3	12–15 months

^{*}For retrospective checking, doses that violate the minimum spacing or age by 4 or fewer days do not need to be repeated. Doses administered 5 days or earlier than the minimum interval of age should be repeated as appropriate for age.⁸

[◇]When a dose is considered invalid due to improper spacing; it will need to be repeated. The repeat dose should be spaced after the invalid dose by a time equal to or greater than the minimum interval between doses.⁸

III. B. CATCH-UP SCHEDULE OF PCV13 FOR CHILDREN <24 MONTHS OF AGE

Doses of PCV13 given to children <24 months of age: Table 9 ⁹		
Age	Vaccination history: # of PCV7 and PCV13 doses received previously	Recommended PCV13 regimen
2–6 months *	0 doses	3 doses, 4 weeks apart; 4 th dose at age 12–15 months
	1 dose	2 doses, 4 weeks apart; 4 th dose at age 12–15 months
	2 doses	1 dose, 4 weeks after most recent dose; 4 th dose at 12–15 months
7–11 months *	0 doses	2 doses, 4 weeks apart; 3 rd dose at 12–15 months
	1 or 2 doses before age 7 months	1 dose at 7–11 months, with a 2 nd dose at 12–15 months ≥8 weeks afterwards
12–23 months	0 doses	2 doses ≥8 weeks apart
	1 dose before age 12 months	2 doses ≥8 weeks apart
	1 dose at ≥12 months	1 dose ≥8 weeks after most recent dose [◇]
	2 or 3 doses <12 months	1 dose ≥8 weeks after most recent dose [◇]
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 PCV13 dose ≥8 weeks after most recent dose [§]

* Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.⁹

III. B. CATCH-UP SCHEDULE FOR PCV13 TO CHILDREN <24 MONTHS OF AGE FOOTNOTES:
Continued

◇ No additional PCV13 doses are indicated for children 12–23 months of age who have received 2 or 3 doses of PCV7 at <12 months of age and at least 1 dose of PCV13 at ≥12 months of age.⁹

§ For children with underlying medical conditions, a supplemental PCV13 dose is recommended through 71 months of age, depending upon the condition. For a list of conditions see Section IV, page 11.⁹

III. C. DOSES OF PCV13 GIVEN TO HEALTHY CHILDREN * 24–59 MONTHS OF AGE: Tables 8 and 11⁹

Age	Vaccination history: # of PCV7 and PCV13 doses received previously	Recommended PCV13 regimen
24–59 months	Unvaccinated or any incomplete schedule	1 dose ≥8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	

* A healthy child is considered complete with 1 dose given at ≥24 months of age.

III. D. SCHEDULES FOR ADMINISTERING PCV13 TO INDIVIDUALS WITH UNDERLYING OR HIGH-RISK MEDICAL CONDITIONS ≥24 MONTHS AND ≤64 YEARS OF AGE BY PCV VACCINATION HISTORY AND AGE.


Age and health status	Vaccination history: # of PCV7 and PCV13 doses received previously	Recommended PCV13 regimen*
24–71 months with underlying medical conditions ⁹ (See Section IV, page 10)	Unvaccinated or any incomplete schedule of <3 doses	2 doses, one ≥8 weeks after the most recent dose and another ≥8 weeks later
	Any incomplete schedule of 3 doses	1 dose ≥8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriated complete PCV7 schedule	
6–18 years of age with high-risk conditions* ¹⁰ (See Section IV, page 10)	Regardless of any previously received PCV7 or PPSV23 doses	1 supplemental dose of PCV13 now if ≥8 weeks after the most recent PCV7 or PPSV23 dose
19–64 years of age with high-risk conditions ⁵ (See Section IV, page 10)	Pneumococcal vaccine naïve	1 dose of PCV13 first, followed by a dose of PPSV23 ≥8 weeks later. ⁵
	Previous vaccination with PPSV23	1 dose of PCV13 ≥1 year after the last PPSV23 dose ^{5,6}

* For children 6–18 years with high-risk conditions, a single PCV13 dose should be given ≥8 weeks after the last PPSV23 dose even if they have received PCV7.¹⁰

◇ For adults 19–64 years of age who require additional doses of PPSV23, the next dose should be given at least 5 years after the most recent dose of PPSV23.^{5, 6}

SECTION III E:³

BOX. Recommended intervals for sequential use of PCV13 and PPSV23 for immunocompetent adults aged ≥ 65 years — Advisory Committee on Immunization Practices, United States



Abbreviations: PCV13 = 13-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

Notes: For adults aged ≥ 65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the recommended interval between PCV13 followed by PPSV23 is ≥ 8 weeks. For those for whom previously received PPSV23 when aged < 65 years and for whom an additional dose of PPSV23 is indicated when aged ≥ 65 years, this subsequent PPSV23 dose should be given ≥ 1 year after PCV13 and ≥ 5 years after the most recent dose of PPSV23.

SECTION III F:³

TABLE. Summary of recommended intervals, by risk and age groups, for persons with indications to receive PCV13 and PPSV23 sequence — Advisory Committee on Immunization Practices, United States, September 2015

Risk group/Underlying medical condition	Intervals for PCV13–PPSV23 sequence, by age group				Intervals for PPSV23–PCV13 sequence, by age group			
	24–71 months	6–18 years	19–64 years	≥65 years	24–71 months	6–18 years	19–64 years	≥65 years
No underlying chronic conditions	NA	NA	NA	≥1 year	NA	NA	NA	≥1 year
Immunocompetent persons	≥8 weeks	NA	NA	≥1 year	≥8 weeks	NA	NA	≥1 year
Chronic heart disease								
Chronic lung disease								
Diabetes mellitus								
Alcoholism ^a								
Chronic liver disease, cirrhosis ^a								
Cigarette smoking ^a								
Immunocompetent persons	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥1 year	≥1 year
Cerebrospinal fluid leak								
Cochlear implant								
Persons with functional or anatomic asplenia	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥1 year	≥1 year
Sickle cell disease/other hemaglobinopathy								
Congenital or acquired asplenia								
Immunocompromised persons	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥8 weeks	≥1 year	≥1 year
Congenital or acquired immunodeficiency								
Human immunodeficiency virus infection								
Chronic renal failure								
Nephrotic syndrome								
Leukemia								
Lymphoma								
Hodgkin disease								
Generalized malignancy								
Iatrogenic immunosuppression								
Solid organ transplant								
Multiple myeloma ^a								


Abbreviation: NA = not applicable, sequential use of PCV13 and PPSV23 is not recommended for these age and risk groups.

^a Underlying medical conditions that are not included in the recommendations for children aged <6 years.

SECTION III G:


ACIP RECOMMENDATIONS FOR SEQUENTIAL ADMINISTRATION AND RECOMMENDED INTERVALS FOR PNEUMOCOCCAL VACCINE-NAÏVE HIGH-RISK PERSONS 19–64 YEARS OF AGE:

5



SECTION III H:

ACIP RECOMMENDATIONS FOR SEQUENTIAL ADMINISTRATION AND RECOMMENDED INTERVALS FOR HIGH-RISK PERSONS 19–64 YEARS OF AGE WITH PRIMARY PPSV23 IMMUNIZATION: ⁵



IV. MEDICAL CONDITIONS OR OTHER INDICATIONS FOR ADMINISTRATION OF PCV13 AND ADMINISTRATION AND REVACCINATION WITH PPSV23^{5, 9, 11, 12, 13}

 2–5 years old*[◇]

 6–64 years old

 ≥65 years old

Risk Group	Age/ Underlying Medical condition	Single dose of PCV13			PPSV23			
		Recommended			Recommended	Revaccination at 5 years ^{§§}		
Immunocompetent persons	Chronic heart disease [§]							
	Chronic lung disease [§]							
	Diabetes Mellitus							
	CSF leaks							
	Cochlear implants							
	Alcoholism							
	Chronic liver disease							
	Cigarette smoking ^{◇◇}							
	Asthma ^{◇‡}							
	Those living in residential care centers							
≥ 65 years						  		
Immunocompromised Persons^{§§} :								

^{§§}Sickle cell disease or other hemoglobinopathies •Congenital or acquired asplenia •Congenital or acquired immunodeficiencies** •HIV infection •Chronic renal failure •Nephrotic syndrome• Leukemia •Lymphoma •Hodgkin disease •Generalized malignancy •Iatrogenic immunosuppression (including immunosuppressive drugs, long-term systemic corticosteroids and radiation therapy) •Solid organ or bone marrow transplant •Multiple myeloma

10/28/15

* 2 doses of PCV13, at least 8 weeks apart if unvaccinated or any incomplete schedule of <3 doses.

◇ PCV13 is recommended for 2–5 years old with asthma if treated with high-dose oral corticosteroid therapy.¹² No PCV13 recommendation for asthma–only diagnosis in 6–18 year olds. Chronic Lung Disease includes asthma for individuals 6–64 years of age for PPSV23.¹⁰

§ PCV13: Particularly cyanotic congenital heart disease and cardiac failure in 2–5 year olds.¹²

‡ PPSV23: Chronic obstructive pulmonary disease, emphysema and asthma in persons ≥6 years of age⁴ and asthma in ≥19 year olds.¹¹

** Includes B–(humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease.)⁴

◇◇ PPSV 23 is recommended for ≥19 year olds who smoke cigarettes.¹¹

§§ **Children and adults younger than age 65** who are at highest risk for serious pneumococcal infection or likely to have a rapid decline in antibody levels should get **2 doses of PPSV23** 5 years apart, with **a third dose after they turn age 65** (if at least 5 years have passed since the last dose).

NOTE: Routine use of PPSV23 is not recommended for American Indian or Alaska natives <65 years of age unless they have medical or other indications. However, public health authorities may recommend PPSV23 for Alaska Natives and American Indians who live in areas in which risk of invasive pneumococcal disease is increased.¹¹

V. A. PPSV23 GENERAL SCHEDULE

Pneumococcal Vaccine*		
Route: SQ or IM		
Dose 0.5mL	Minimum Age	Minimum Interval (If dose 2 is needed)
1	≥65 years of age	5 years** ◇◇
1	2–64 years with high–risk condition ◇§ ‡	

* PPSV23 is NOT indicated for children <2 years of age since the antibody response to most capsular polysaccharide types is poor in this age group. Children under the age of 2 years should receive pneumococcal conjugate vaccine (PCV13) instead.¹³

◇ For retrospective checking for individuals' ≤19 years of age, doses that violate the minimum spacing or age by 4 or fewer days do not need to be repeated. Doses administered 5 days or earlier than the minimum interval or age should be repeated as age appropriate.⁸

§ One dose of pneumococcal vaccine is recommended for children and adolescents who are at least 2 years of age and at high risk. See Section IV page 10. Children with cochlear implants who have completed the PCV13 series should wait at least 8 weeks after completing PCV13 before receiving PPSV23.¹³

‡ High-risk children aged 24–59 months should also be considered for pneumococcal conjugate vaccine (PCV13). See Section IV page 11.⁹

** For children who are immunocompromised or who have functional or anatomic asplenia, a single revaccination is recommended if 5 years or more have elapsed after the previous dose.^{9, 13}

◇◇ For adults ≥65 years who inadvertently received PPSV23 ≤12 months after PCV13, do not repeat either dose. Although optimal timing was not followed, both doses will be considered valid.^{3, 6}

VI. CONTRAINDICATIONS

PCV13

1. Persons who experienced an anaphylactic reaction to a previous dose of PCV7, PCV13 or any diphtheria toxoid-containing vaccine.¹
2. Do not give Menactra[®] to children ≤ 2 years of age with functional or anatomic asplenia, including sickle cell, due to potential interference with the immune response to PCV13.⁴

PPSV23

1. Persons who experienced an anaphylactic reaction to a previous dose of pneumococcal vaccine or a vaccine component.²

VII. PRECAUTIONS for PCV13 and PPSV23

1. Women who are at high risk of pneumococcal disease and who are candidates for either PCV13 or PPSV23 should be vaccinated before pregnancy, if possible.²
2. Persons with acute, moderate or severe illness with or without fever may choose to delay immunization until symptoms have improved.¹

VIII. A. SIDE EFFECTS AND ADVERSE REACTIONS

Percentage of U.S. subjects 2-month –17 years of age reporting solicited local reactions within 7 days after vaccination with Prevnar 13.¹

	Prevnar 13	Prevnar 13	Prevnar 13	
Number followed for safety	N = 1375–1612 [*] %	N = 209–238 [§] %	N = 592 ^{**} %	
Age in Years	Children 2–15 months	Children 24–59 months	Children 5–17 years	
Local reaction, injection site			5–9	10–17
Pain	62.5	62.6	86.8	89.0
Redness	24.3	35.4	42.9	30.2
Swelling	20.1	20.7	37.6	36.9
Systemic complaints	N = 1360–1707 [◇]	N=209–236 [‡]	N=592 ^{◇◇}	
Irritability	85.6	45.8	31.2	25.2
Fever	24.3	8.1	6.1	5.6
Decreased appetite	48.3	28.1	22.9	22.9
Increased sleep	71.5	18.8	21.2	26.6
Decreased sleep	42.5	14.8	5.7	18.8
Hives			1.9	1.4
Limitation of arm movement	10.4 [*]	10.7 [§]		

^{*}Table 3 page 8²

[◇]Table 4 page 9²

[§]Table 7 page 12²

[‡]Table 8 page 13²

^{**}Table 9 page 14²

^{◇◇}Table 10 page 14²

VIII.B. SIDE EFFECTS AND ADVERSE REACTIONS

Solicited adverse events with Prevnar 13 in adults 50 to ≥70 years of age

	Prevnar 13 N = 152–322	Prevnar 13 N = 270–370	Prevnar 13 N = 306–362
Age in Years	50–59 years [*]	60–64 years [◇]	≥70 years [§]
Solicited local reactions	%	%	%
Pain	88.8	69.2	51.7
Redness	15.8	12.2	10.8
Swelling	21.7	10.0	10.4
Solicited systemic events			
Fatigue	63.3	50.5	34.0
Fever ≥38°C	1.5	4.2	1.0
Headache	65.9	49.7	23.7
Chills	19.6	19.9	7.9
Rash	14.2	8.6	7.3
Vomiting	6.9	3.1	1.7
Decreased appetite	25.3	14.7	10.4
Generalized new muscle pain	61.8	46.9	36.8
Generalized aggravated muscle pain	39.9	22.0	20.6
Generalized new joint pain	31.5	15.5	12.6
Generalized aggravated joint pain	25.6	14.0	11.6
Limitation of arm movement	40.7	23.5	10.5

^{*}Table 11 and 13, study 6: Percentage of subjects with solicited local reactions within 14 days after vaccination with Prevnar 13 in unvaccinated adults. Pages 17 and 19¹

[◇]Table 11 and 13, study 8: Percentage of subjects with solicited local reactions within 14 days after vaccination with Prevnar 13 in adults previously unvaccinated with PPSV23. Pages 17 and 19.¹

[§]Table 12 and 14, study 7: Percentage of subjects With solicited Local reactions within 14 days after vaccination with Prevnar 13 in adults previously vaccinated with PPSV23. Pages 18 and 20.¹

VIII.C. SIDE EFFECTS AND ADVERSE REACTIONS

Incidence of injection-site and systemic complaints in adults ≥50 years of age receiving their first (Initial) or second (revaccination) dose of Pneumovax 23.²

Number followed for Safety	Pneumovax 23 Initial Vaccination N =444 %	Pneumovax 23 Revaccination N=564 %
Age in Years	≥50 years	≥50 years
Solicited events: injection site		
Pain	60.0	77.2
Redness	16.4	34.5
Swelling	20.3	39.8
Unsolicited events: injection site		
Bruising	0	1.1
Itching	0.2	1.6
Solicited systemic events		
Fatigue	13.2	17.9
Chills	2.7	7.8
Muscle pain	11.9	17.3
Headache	17.6	18.1
Unsolicited systemic events		
Fever	1.4	2.0
Diarrhea	1.1	0.7
Indigestion	1.1	1.1
Nausea	1.8	1.8
Back Pain	0.9	0.9
Neck pain	0.7	1.5
Upper Respiratory Infection	1.8	2.6
Pharyngitis	1.1	0.4

Table 1, page 4²

IX. PCV13 AND PPSV23 OTHER CONSIDERATIONS

1. **Adverse Events:** Epinephrine hydrochloride solution (1:1,000) and other appropriate agents and equipment must be available for immediate use in case of anaphylactic or acute hypersensitivity reaction.⁸
2. **Lactation:** It is not known whether pneumococcal vaccines are excreted in human milk. Use with caution in nursing mothers.^{1, 2}
3. **Simultaneous administration** of PCV13 and PPSV23 is NOT recommended. See pgs. 3–8 for the necessary minimum interval between doses.^{3, 6}
4. May give Zostavax[®] at same visit as PPSV23.¹⁴
5. The use of antibiotic prophylaxis in children under five years of age with functional or anatomical asplenia, and sickle cell disease continues to be recommended. Parents should consult with their treating physician as to whether children who have not experienced invasive pneumococcal disease and have received the recommended pneumococcal immunization should discontinue prophylaxis after 5 years of age.¹⁶
6. When an elective splenectomy is performed for any reason, administer PCV13 at least 2 weeks prior to splenectomy. If pneumococcal vaccine is not administered before surgery it should be administered after the procedure as soon as patient's condition is stable.¹⁶
7. Immunization should precede the initiation of immunocompromising therapy by at least two weeks.¹⁶
8. Children who have experienced invasive pneumococcal disease should receive all recommended doses of a pneumococcal conjugate vaccine as appropriate for their age and underlying condition. The full series of scheduled doses should be completed even if the series is interrupted by an episode of invasive pneumococcal disease.⁹
9. Children with diseases associated with immunosuppressive therapy or radiation therapy and solid organ transplantation may have a diminished response to the vaccine.¹⁶
10. The use of pneumococcal PCV13 does not replace the use of PPSV23 pneumococcal polysaccharide vaccine (PPSV23) in children ≥24 months of age with sickle cell disease, asplenia, HIV infection, chronic illness or who are otherwise immunocompromised.¹⁶
11. **Hematopoietic stem cell transplants (HSCT)** and pneumococcal vaccine: ACIP recommends that one dose of PPSV23 be given to a HSCT ≥8 weeks following the 3rd or last dose of PCV13 revaccination dose.¹⁶

X. STORAGE AND HANDLING

All clinics and pharmacies enrolled with the VFC program must **immediately** report any storage and handling deviations to their Oregon Immunization Program health educator. The health educator assignment map is located at: http://bit.ly/HE_Map

Vaccine	Temp	Storage Issues	Notes
Pevnar 13[®] 1	Store at 2°–8°C (36°F–46°F)	After shipping may arrive at temperatures between 2°C to 25°C (36°F–77°F). Do not use if vaccine has been frozen. Report to health educator.	No natural rubber latex
Pneumovax[®] 2	Store at 2°–8°C (36°F–46°F)	Do not use after expiration date.	No natural rubber latex

XI. ADVERSE EVENTS REPORTING

Adverse events following immunization must be reported to the Vaccine Adverse Events Reporting System (VAERS). The VAERS online report form is available at <https://vaers.hhs.gov/esub/step1>.

A pharmacist who administers any vaccine must report the following elements to the OHA ALERT Immunization Information System in a manner prescribed by OHA within 15 days of administration. This replaces the former requirement to notify the primary health care provider. A pharmacist is not required to notify the primary health care provider. Oregon Administrative Rule 855-019-0290-(2)(3).^{17,18}

To request this material in an alternative format (e.g., Braille) or to clarify any part of the above order, contact the Oregon Health Authority Immunization Program at 971.673.0300 and 711 for TTY. For other questions, consult with the vaccine recipient’s primary health care provider or a consulting physician.

Electronic copy of this protocol is available at:

<http://1.usa.gov/PharmacyImmunizationProtocols>

REFERENCES

1. PCV13 (Prevnar®13) 2012 package insert. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201669.pdf. Accessed 11 September 2015.
2. Merck & Co., Inc. 2011 Pneumovax® 23 prescribing information. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM257088.pdf. Accessed 11 September 2015.
3. CDC. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2015. 64(34)944–47. Available at: www.cdc.gov/mmwr/pdf/wk/mm6434.pdf. Accessed 03 September 2015.
4. CDC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR2014; 63(24):527–30. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6324a2.htm?s_cid=mm6324a2_e. Accessed 17 December 2014.
5. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61(40);816–19. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm. Accessed 11 September 2015.
6. Immunize.org. Ask The Experts. Pneumococcal vaccine. Scheduling and Documenting Vaccines. Available at: www.immunize.org/askexperts/experts_pneumococcal_vaccines.asp#ppsv23_misc. Accessed 11 September 2015.
7. CDC. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older, MMWR 2012,61;394–95. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a3.htm Accessed 4 November 2014.
8. CDC. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(2);1–64. Available at: www.cdc.gov/mmwr/pdf/rr/rr6002.pdf. Accessed 18 August 2015.

9. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2010;59(RR11);1–18. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm?s_cid=rr5911a1_e. Accessed 4 November 2014.
10. CDC. Use of 13–valent pneumococcal conjugate vaccine and 23–valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR 2013; 62(25); 521–24. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6225a3.htm. Accessed 4 November 2014.
11. CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23–valent pneumococcal polysaccharide vaccine (PPSV23) MMWR 2010 59:1102–06. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm. Accessed 4 November 2014.
12. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP). 2010. MMWR 2010; 59:258–61. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm Accessed 4 November 2014.
13. Immunization Action Coalition. Pneumococcal vaccines: CDC answers your questions. Available at: www.immunize.org/catg.d/p2015.pdf. Accessed 09 September 2015.
14. Tseng, H. F., Smith, N. et al. 2011. *Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine*. Vaccine 29 (2011) 3628–32 Abstract available at Science Direct. Available at: www.sciencedirect.com/science/article/pii/S0264410X11003707. Accessed 4 November 2014.
15. CDC. PCV13 recommendations, scenarios and Q & As for healthcare professionals about PCV13 for adults. December 2014. Available at: www.cdc.gov/vaccines/vpd-vac/pneumo/vac-PCV13-adults.htm. Accessed 31 March 2015.
16. American Academy of Pediatrics. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Pickering LK, ed. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:74–87. Accessed 11 September 2015.
17. State of Oregon, Administration of Vaccines by Pharmacists: 855–019–270. Available at: www.oregon.gov/pharmacy/Imports/Rules/December10/855-019_Perm.pdf Accessed 11 August 2015.

18. Oregon Administrative Rule. Board of Pharmacy. Division 19. Licensing of pharmacists: 855-019-0290 (2). Available at: www.oregon.gov/pharmacy/Imports/Rules/December10/855-019_Perm.pdf Accessed 11 September 2015.